Clinical Trial Update: INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma. [Phase 2]

View source ↗

Summary

The Phase II trial of gemcitabine plus irinotecan for relapsed or refractory Non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Irinotecan (Irinotecan)

Snippet

Sponsor: University of New Mexico | Conditions: Non-Hodgkin's Lymphoma, Cancer | Phase 2 | Status: COMPLETED